Oxidants, antioxidants and the current incurability of metastatic cancers
- PMID: 23303309
- PMCID: PMC3603456
- DOI: 10.1098/rsob.120144
Oxidants, antioxidants and the current incurability of metastatic cancers
Abstract
The vast majority of all agents used to directly kill cancer cells (ionizing radiation, most chemotherapeutic agents and some targeted therapies) work through either directly or indirectly generating reactive oxygen species that block key steps in the cell cycle. As mesenchymal cancers evolve from their epithelial cell progenitors, they almost inevitably possess much-heightened amounts of antioxidants that effectively block otherwise highly effective oxidant therapies. Also key to better understanding is why and how the anti-diabetic drug metformin (the world's most prescribed pharmaceutical product) preferentially kills oxidant-deficient mesenchymal p53(- -) cells. A much faster timetable should be adopted towards developing more new drugs effective against p53(- -) cancers.
References
-
- McLaughlin L. 1975. War-on-cancer is called ‘sham’, ‘wishful thinking’ by Nobel winner. Boston Herald American, March 7
-
- Jones S, Vogelstein B, Velculescu VE, Kinzler KW. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801.10.1126/science.1164368 (doi:10.1126/science.1164368) - DOI - DOI - PMC - PubMed
-
- Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–113410.1016/j.cell.2010.06.011 (doi:10.1016/j.cell.2010.06.011) - DOI - DOI - PMC - PubMed
-
- Zeng Q, et al. 2012. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc. Natl Acad. Sci. USA 109, 1127–113210.1073/pnas.1111053108 (doi:10.1073/pnas.1111053108) - DOI - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous